Spasticity can be a major symptom in all forms of MS, and there are anedoctical reports that this symptom can be increased during treatment of relapsing forms of MS with interferon-beta- Ib ( in contrast to considerable and consistent improvement burden as shown by MRI and the clinical manifestations of the disease which clearly improve). Here we report that in primary progressive MS patients undergoing compassionate treatment with the same drug spasticity became increased use of antispastic therapy. Such a possibility which clearly needs further investigation has to be taken into account in the planning of new clinical trials in this form of MS.
|Number of pages||1|
|Journal||Italian Journal of Neurological Sciences|
|Publication status||Published - 1997|
ASJC Scopus subject areas
- Clinical Neurology